Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dbc-664

Phase 1

DDuboce Biopharmaceuticals, Inc.

Dbc-664 is one of 17 therapeutic programs targeting Germ Cell Tumor. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

16

Competitors

Pipeline

Status by Indication[2][1]

Indication

Germ Cell TumorRecruiting

Germ Cell TumorPhase 1

Recruiting

Competition

Competitive Landscape

18 competitors in Germ Cell Tumor

#DrugCompanyPhaseTrials

Ellence

Afinitor

Gemzar

Johnson & Johnson

Iressa

Antabuse

Taxol

Blenoxane

Bristol-Myers Squibb

Vepesid

Paraplatin

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Recruiting

Germ Cell Tumor

NCT07705035

Clinical

Trials by Indication[1]

Germ Cell Tumor1 trial

A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of DBC-664 in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting·DDuboce Biopharmaceuticals, Inc.·Phase 1·NCT07705035·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dbc-664. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dbc-664. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Duboce Biopharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: DDuboce Biopharmaceuticals, Inc.

Related News